Awakn Life Sciences: Business And Corporate Update For Psychedelics Biotech
Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has just published its business and corporate updates.
Numinus Wellness Announces Q3 Results
Mental healthcare company advancing psychedelic-assisted therapies Numinus Wellness Inc. (OTCQX: NUMIF) recently announced its fiscal quarter results for the three and nine months ended May 31, 2022.
Michael Pollan’s ‘How To Change Your Mind’ Now On Netflix, Here Are Reactions From Experts
Michael Pollan's 2018 book “How To Change Your Mind: What the science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence” is available on Netflix (NASDAQ: NFLX).
New Optimi Supply Agreement: Psilocybin For Phase 1 Trial On Microdosing For Wellbeing, No Hallucinogenic Effects
Canadian psychedelics company Optimi Health Corp. (OTCQX: OPTHF) signed a supply agreement with the Bloom Psychedelic Therapy And Research Centre, a Calgary-based provider of psychedelic-assisted therapies for mental health conditions.
PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson’s And Motor Disorders Treatment
Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB: PHRRF) has been granted a Notice of Allowance by the U.S.
Filament Begins First Ever FDA-Approved Clinical Trial On Naturally-Derived Psychedelic Drugs
Clinical-stage natural psychedelics company Filament Health Corp.
BetterLife’s Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs
Biotech psychedelics company BetterLife Pharma Inc. (OTCQB: BETRF) in collaboration with the Carleton University Dept.